CGEM Cullinan Therapeutics
- 23.030
- -1.100-4.56%
- 23.490
- +0.460+2.00%
Cullinan Therapeutics News
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed,
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target
HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics with a Buy and maintains $28 price target.
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28
H.C. Wainwright analyst Edward White maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 3
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination With a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung
Cullinan Therapeutics Files to Sell 14.4M Shares of Common Stock for Holders
Cullinan Therapeutics Shares Are Trading Lower After the Company Reported Q1 Results and Provided a Corporate Update.
Cullinan Therapeutics Shares Are Trading Lower After the Company Reported Q1 Results and Provided a Corporate Update.
Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.
Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Lowers Price Target to $28
HC Wainwright & Co. analyst Edward White maintains Cullinan Therapeutics with a Buy and lowers the price target from $29 to $28.
Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $36 Price Target
Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $36 price target.
Cullinan Therapeutics | 10-Q: Quarterly report
Cullinan Therapeutics 1Q Loss/Shr 86c >CGEM
Cullinan Therapeutics 1Q Loss/Shr 86c >CGEM
Press Release: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster s
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing
Jennifer Michaelson, Chief Scientific Officer, on May 06, 2024, sold 63,606 shares in Cullinan Therapeutics (CGEM) for $1,796,676. Following the Form 4 filing with the SEC, Michaelson has control over
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
Cullinan Therapeutics(CGEM.US) Officer Sells US$1.8 Million in Common Stock
$Cullinan Therapeutics(CGEM.US)$ Officer Michaelson Jennifer sold 63,606 shares of common stock on May 6, 7, 2024 at an average price of $28.25 for a total value of $1.8 million.Source: Announcement W
Investor Sentiment Swings in Favor of Cullinan Therapeutics (NASDAQ:CGEM)
Cullinan Oncology Initiated at Buy by Stifel
Cullinan Oncology Initiated at Buy by Stifel
Cullinan Therapeutics (CGEM.US) was first covered by Stifel, giving it a buy rating, with a target price of $40.00.
Cullinan Therapeutics (CGEM.US) was first covered by Stifel, giving it a buy rating, with a target price of $40.00.
Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40
Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $40.
Analysis
Price Target
No Data
